Hybridoma technology revolutionized the field of antibody drug discovery by enabling the mass production of monoclonal antibodies to an antigen of interest. Created by fusing antibody-producing B cells with immortalized myeloma cells, hybridoma cells produce specific monoclonal antibodies. However, these immortalized cells carry certain limitations for antibody production, including contamination risks, genomic instability, low yield, culture challenges, and storage space constraints.
Hybridoma sequencing has emerged as a powerful tool to overcome these hurdles. By sequencing the variable heavy (VH) and variable light (VL) domains of monoclonal antibodies produced from a hybridoma cell line, we deliver antibody-coding nucleotide sequences, which can be cloned into expression vectors for recombinant antibody production in many expression hosts, such as mammalian, insect and bacterial cells. Hybridoma sequencing is also the answer to hybridoma clone authentication.
